Morgan Stanley Vera Therapeutics, Inc. Transaction History

Morgan Stanley

$1.49 Trillion
Q2 2025

A detailed history of Morgan Stanley transactions in Vera Therapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 2,238,252 shares of VERA stock, worth $47.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,238,252

Previous 440,689 407.9%

Holding current value

$47.3 Million

Previous $10.6 Million 398.19%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 15, 2025	BUY	$18.86 - $32.0 $33.9 Million - $57.5 Million	1,797,563 Added 407.9%	2,238,252 $52.7 Million
Q1 2025 May 15, 2025	BUY	$24.02 - $43.22 $2.69 Million - $4.85 Million	112,174 Added 34.15%	440,689 $10.6 Million
Q4 2024 Feb 14, 2025	SELL	$38.64 - $49.75 $485,357 - $624,909	-12,561 Reduced 3.68%	328,515 $13.9 Million
Q3 2024 May 14, 2025	BUY	$34.09 - $46.71 $1.21 Million - $1.66 Million	35,638 Added 11.67%	341,076 $15.1 Million
Q3 2024 Nov 14, 2024	BUY	$34.09 - $46.71 $1.21 Million - $1.66 Million	35,638 Added 11.67%	341,076 $15.1 Million
Q2 2024 May 14, 2025	SELL	$33.72 - $48.82 $778,156 - $1.13 Million	-23,077 Reduced 7.02%	305,438 $11.1 Million
Q2 2024 Oct 17, 2024	SELL	$33.72 - $48.82 $41.5 Million - $60.1 Million	-1,231,352 Reduced 80.12%	305,438 $11.1 Million
Q2 2024 Aug 14, 2024	SELL	$33.72 - $48.82 $41.5 Million - $60.1 Million	-1,231,352 Reduced 80.12%	305,438 $11.1 Million
Q1 2024 Oct 17, 2024	BUY	$14.91 - $49.14 $18.4 Million - $60.5 Million	1,231,352 Added 403.14%	1,536,790 $66.3 Million
Q1 2024 Aug 16, 2024	BUY	$14.91 - $49.14 $8.08 Million - $26.6 Million	541,950 Added 54.48%	1,536,790 $66.3 Million
Q1 2024 May 15, 2024	BUY	$14.91 - $49.14 $8.08 Million - $26.6 Million	541,950 Added 54.48%	1,536,790 $66.3 Million
Q4 2023 Aug 16, 2024	BUY	$9.29 - $16.0 $6.4 Million - $11 Million	689,402 Added 225.71%	994,840 $15.3 Million
Q4 2023 Feb 13, 2024	BUY	$9.29 - $16.0 $744,073 - $1.28 Million	80,094 Added 8.76%	994,840 $15.3 Million
Q3 2023 Nov 15, 2023	SELL	$13.71 - $19.64 $730,729 - $1.05 Million	-53,299 Reduced 5.51%	914,746 $12.5 Million
Q2 2023 Aug 14, 2023	BUY	$6.11 - $17.83 $5.67 Million - $16.5 Million	927,377 Added 2280.36%	968,045 $15.5 Million
Q1 2023 May 15, 2023	BUY	$5.41 - $18.3 $135,872 - $459,604	25,115 Added 161.48%	40,668 $315,000
Q4 2022 Feb 14, 2023	SELL	$15.74 - $22.19 $116,586 - $164,361	-7,407 Reduced 32.26%	15,553 $300,000
Q3 2022 Nov 14, 2022	BUY	$13.27 - $22.31 $258,698 - $434,933	19,495 Added 562.63%	22,960 $489,000
Q2 2022 Oct 27, 2022	SELL	$12.82 - $23.4 $192,979 - $352,240	-15,053 Reduced 81.29%	3,465 $47,000
Q2 2022 Aug 15, 2022	SELL	$12.82 - $23.4 $192,979 - $352,240	-15,053 Reduced 81.29%	3,465 $47,000
Q1 2022 Oct 27, 2022	BUY	$17.8 - $28.06 $267,943 - $422,387	15,053 Added 434.43%	18,518 $435,000
Q1 2022 May 13, 2022	SELL	$17.8 - $28.06 $145,479 - $229,334	-8,173 Reduced 30.62%	18,518 $435,000
Q4 2021 Feb 14, 2022	BUY	$15.01 - $35.8 $70,321 - $167,723	4,685 Added 21.29%	26,691 $714,000
Q3 2021 Nov 15, 2021	BUY	$13.71 - $30.6 $301,702 - $673,383	22,006 New	22,006 $382,000

Others Institutions Holding VERA

# of Institutions

199

Shares Held

64.6M

Call Options Held

1.58M

Put Options Held

365K

View Full List

About Vera Therapeutics, Inc.

Ticker VERA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 27,042,300
Market Cap $572M
Description
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with ...

More about VERA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account